Trial Profile
A phase I study of LAM-001 for lymphangioleiomyomatosis and related indications.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Dec 2023
Price :
$35
*
At a glance
- Drugs Sirolimus (Primary)
- Indications Lymphangioleiomyomatosis
- Focus Adverse reactions
- 06 Feb 2016 New trial record